

## Comment November 2021


In view of new lockdown fears in Europe, small-cap Swiss equities experienced a noticeable setback in November. Once again, almost all equities were hit by a rapid negative spiral, including value stocks. However, the highly valued growth stocks, which are not in the fund portfolio, came under disproportionate pressure.

**DKSH, Also, BKW, Piazza, Groupe Minoteries** and **Holdigaz** supported the fund's performance. The share price performance of **Jungfraubahn, Cosmo, MCH Group, IVF Hartmann** and **Vifor Pharma** was negative. However, the new CEO Abbas Hussain of **Vifor**, which specializes in iron deficiency, nephrology and cardiovascular diseases, made an excellent impression at the CS Conference on Swiss Equities. In addition to the clear strategic statements, we liked the cost focus. In our opinion, there is a high chance that together with the expected news, the momentum in the stock will turn back to the positive side. The potential approval of Ferinject in China or the commercialisation of Rayaldee in Europe and Korsuva in the US may be triggers for such a turnaround. It is also essential for Vifor that the iron franchise remains on the road to recovery after the pandemic related slump. The strengthening of the pipeline through the recent acquisitions of Sanifit Therapeutics and Inositec are of secondary importance for the investment case today. However, the broadening of the pipeline opens up new opportunities and is to be welcomed. **IVF Hartmann** had to adjust the forecast for 2021 repeatedly. Higher procurement and logistics costs and an oversaturation of the supply of protective goods continue to weigh. Nevertheless, operating profit is expected to be in line with the first half of the year. With conservative assumptions, the valuation is currently at an extremely attractive point and offers a high upside potential in case of an operational improvement. We are not satisfied with the fund's performance so far this year. We are consistently pushing ahead the broader positioning of the portfolio towards solid Swiss companies with above-average balance sheet quality. Attractive opportunities for this are sufficiently available on the Swiss stock market.

## Top 10 positions

Company	Weight
IVF Hartmann	9.1%
Vaudoise Assurances	8.8%
Holdigaz	7.5%
Cham Group	6.5%
BKW	6.2%
COSMO Pharmaceuticals	5.6%
Jungfraubahn	5.1%
Groupe Minoteries	4.9%
Vifor Pharma	4.6%
Arbonia	4.3%

## Performance since launch



## Key figures

Net Asset Value	CHF 1'629.60
Number of units	111'767
Total Net Asset Value	CHF 182.1m

## Performance

Duration	Fund
1 month	-5.3%
3 months	-7.7%
12 months	2.9%
3 years p.a.	0.7%
5 years p.a.	0.7%
since inception p.a.	8.8%
Year	Fund
2021	-0.3%
2020	-0.9%
2019	9.8%
2018	-15.2%
2017	10.3%
since inception	322.2%

## Risk ratios (rolling over the last 3 years)

Volatility (p.a.)	14.6%
Sharpe ratio (-0.72% Risk free rate)	0.05
Beta (vs. SPI Small & Mid Cap TR Index)	0.73


## Exposure

Long Position	102.9%
Hedge Position	6.1%
Net Position	96.8%
Cash	3.2%
Absolut Position	109.0%

## Top 3 performers in November 2021

Company	Perf.
BKW	3.3%
Groupe Minoteries	3.1%
ALSO	3.0%

## Breakdown by sectors



Health Care	25.8%	Industrials	16.1%
Financials	13.9%	Utilities	13.5%
Real Estate	9.4%	Consumer Staples	8.9%
Communication Serv.	5.3%	IT	2.8%
Materials	2.4%	Energy	0.0%
Consumer Discr.	-1.3%	Cash	3.2%

## Sustainability

### Applied ESG characteristics

- Exclusion Criteria
  Reporting  
 Integration
  Benchmark

This is a financial product within the meaning of Art. 8 of Regulation (EU) 2019/2088 (Disclosure Regulation).

## Last 5 distributions to investors

(Amounts in CHF per unit)

Date	Gross dividend (subject to VAT)	Capital (without VAT deduction)	Total dividend (gross)
05.07.2017	-	100	100
21.03.2018	-	100	100
20.03.2019	-	40	40
18.03.2020	6	34	40
27.04.2021	-	40	40

## Investment philosophy

The equity fund invests in Swiss companies from the small & mid cap segment. The investment focus is on companies that receive lesser attention by investors, with an overweighting of defensive value stocks. AMG Fonds' own in-depth equity analysis is used for stock selection and risk conscious fund management. Within the framework of the bottom-up approach, particular attention is paid to the financial ratios and balance sheet ratios. The management of the companies is the decisive factor for a fundamentally long-term commitment. This approach results in a niche portfolio in a special segment of the Swiss equity market that offers solid development potential with lower volatility.

## Fund facts

Domicile of fund	CH
Legal form	Contractual investment fund
Investment universe	Small & Mid Caps Switzerland
Investment manager	AMG Fondsverwaltung AG, Zug
Management company	LLB Swiss Investment Ltd, Zurich
Custodian bank	Bank J. Safra Sarasin Ltd, Basel
Launch date	15.11.2004
Recommended investment horizon	5 years
Reference currency	CHF
ISIN / Bloomberg-Ticker	CH0019597530 / AMGSSCH SW
Distributions	distributing (Dividend & Capital Gain)
Subscription and redemption	daily (cut-off 09.00 CET)
Performance Fee	8% over 2% Hurdle, with High Water Mark
High Water Mark and Hurdle	CHF 1'843.18
Tax transparency	CH, AT
Tax status Germany	Equity fund pursuant to InvStG with partial exemption
Registered for public distribution	CH

## Fee structure

Subscription and redemption fee	none
Management fee p.a.	1.00%
Total expense ratio p.a. (per 30.06.2021; TER, before profit sharing)	1.19%

## Contact - Portfolio management



**Manuel Bottinelli**  
bottinelli@amgfonds.ch  
+41 (0)41 726 71 62



**Patrick Hofer**  
hofer@amgfonds.ch  
+41 (0)41 726 71 76

## AMG Fondsverwaltung AG

Bahnhofstrasse 29  
CH-6300 Zug  
+41 (0)41 726 71 71  
www.amgfonds.ch

## Legal notice

This document is promotional material. This document does not constitute an offer or recommendation for the purchase or sale of investment funds. We do not accept any liability for inaccurate information. Past performance is not a reliable indicator of current or future performance. The performance figures do not include commissions and costs, which arise at subscription and redemption of units. The price of a unit can rise as well as fall. The fund does not compare its performance with a benchmark index. The legal fund documents are available free of charge from AMG Fondsverwaltung AG at www.amgfonds.ch.